Wells Fargo sets USD 5.00 target for Zentalis Pharmaceuticals stock

Published on 10/02/2026 at 02:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zentalis posted a USD 77.64 million GAAP loss in Q2 2026. For Zentalis Pharmaceuticals stock, market value stood at USD 185.4 million on October 1, 2026.

ZNTL, US98943L1070, Illustration mit AI erstellt.

Wells Fargo analyst Yanan Zhu maintained a Hold rating and set a USD 5.00 price target for Zentalis Pharmaceuticals (ISIN US98943L1070) on September 29, 2026, according to Markets Insider. The note puts the analyst view against a clinical-stage biotechnology company still funding late-stage cancer studies.

Wells Fargo keeps a cautious view

The USD 5.00 target is materially below the USD 8.17 consensus target also cited by Markets Insider on September 30, 2026. That spread makes analyst disagreement a central part of the ZNTL story, especially while the company remains focused on development rather than product revenue.

MarketBeat reported on September 16, 2026, that William Blair initiated coverage with an Outperform rating and a USD 8.00 price objective. MarketBeat also listed five Buy ratings, four Hold ratings and one Sell rating, showing a divided analyst group rather than a uniform bullish view.

Second-quarter loss widens sharply

Zentalis reported a GAAP net loss of USD 77.64 million for the second quarter of 2026, compared with USD 26.87 million a year earlier, according to MarketBeat on September 30, 2026. The loss therefore widened 188.87 percent year over year.

The same report showed quarterly earnings per share of minus USD 0.59, missing the USD 0.49 consensus estimate by USD 0.10. The figures reflect the cost of advancing azenosertib, the company's oral WEE1 inhibitor, through studies in ovarian cancer and other tumor types.

Funding supports the oncology pipeline

Zentalis is developing azenosertib as a potential treatment for cancer, with ovarian cancer among the lead areas, according to the company's investor-relations profile dated October 2, 2026. The company priced an USD 80.5 million common-stock offering on August 14, 2026, according to MarketScreener, giving the pipeline additional financing while increasing dilution considerations.

Market value remains below yearly high

ZNTL had a market capitalization of USD 185.4 million as of October 1, 2026. The Nasdaq-listed stock's 52-week range was USD 1.21 to USD 6.95, leaving the current market value in a wide valuation corridor as analysts assess clinical progress and financing needs.